Labcorp , a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD ...

On November 18, Lunit, a medical artificial intelligence (AI) company, announced that it has entered into a strategic partnership with Labcorp, a ...

This growth is primarily driven by the rising global cancer incidence, increasing preference for non-invasive diagnostic ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

The launch of Sandoz's Tyruko biosimilar of Tysabri (natalizumab) comes two years after the product was approved by the FDA, ...

The global healthcare contract research organization (CRO) market is projected to expand significantly from USD 55.84 billion in 2024 to USD 105.73 billion by 2033, at a CAGR of 7 ...

Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM ESTCompany ParticipantsKevin Conroy - Chairman ...

AABB-accredited DNA testing is the standard when results need to stand up in court or be accepted by government agencies. If ...

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease.

A research team in Brazil has published animal data showing a copper chelating compound can cross the blood brain barrier, ...

The U.S. neurology clinical trials market is positioned for growth, driven by advancements in neuroscience, rising healthcare ...

Robust growth is propelled by rising demand for regulatory writing, clinical documentation, and drug development. Medical ...